G-CSF not worth the extra cost in elderly patients with NHL

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1463, 2004-01, pp. : 6-6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Antineoplastics/pirarubicin: Acute myeloid leukaemia in elderly patients, treated with cytarabine, aclarubicin and G-CSF: 3 case reports

Reactions Weekly, Vol. 1, Iss. 1238, 2009-01 ,pp. : 6-7

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Amphotericin B plus G-CSF Compared with Amphotericin B Monotherapy: Treatment of Presumed Deep-Seated Fungal Infection in Neutropenic Patients in the UK

By Flynn T.N.

PharmacoEconomics, Vol. 16, Iss. 5, 1999-11 ,pp. : 543-550

Adis International

Access to resources Recommend Favorite

G-CSF cost-neutral for early-stage breast cancer

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 646, 2012-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

G-CSF vs GM-CSF: cost of adverse events makes all the difference

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 277, 2000-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

G-CSF linked to GVHD

Reactions Weekly, Vol. 1, Iss. 1327, 2010-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite